Serotype distribution of Streptococcus pneumoniae causing invasive disease in the Republic of Ireland

SUMMARY The 7-valent pneumococcal conjugate vaccine (PCV7) was included in the routine infant immunization schedule in Ireland in September 2008. We determined the serotype of 977 S. pneumoniae isolates causing invasive disease between 2000–2002 and 2007–2008, assessed for the presence of the recently described serotype 6C and determined the susceptibility of isolates during 2007–2008 to penicillin and cefotaxime. Serotype 14 was the most common serotype during both periods and 7·7% of isolates previously typed as serotype 6A were serotype 6C. During 2000–2002 and 2007–2008, PCV7 could potentially have prevented 85% and 74% of invasive pneumococcal disease in the target population (i.e. children aged <2 years), respectively. The level of penicillin non-susceptibility was 17% in 2007–2008. Ongoing surveillance of serotypes is required to determine the impact of PCV7 in the Irish population and to assess the potential of new vaccines with expanded valency.

[1]  J. Marimón,et al.  Prevalence and molecular characterization of Streptococcus pneumoniae serotype 6C causing invasive disease in Gipuzkoa, northern Spain, 1990–2009 , 2010, European Journal of Clinical Microbiology & Infectious Diseases.

[2]  S. Clarke,et al.  Increase in Serotype 6C Pneumococcal Carriage, United Kingdom , 2010, Emerging infectious diseases.

[3]  F. Kong,et al.  First report of putative Streptococcus pneumoniae serotype 6D among nasopharyngeal isolates from Fijian children. , 2009, The Journal of infectious diseases.

[4]  D. Greenberg,et al.  Introduction and proliferation of multidrug-resistant Streptococcus pneumoniae serotype 19A clones that cause acute otitis media in an unvaccinated population. , 2009, The Journal of infectious diseases.

[5]  C. Whitney,et al.  PCR-Based Quantitation and Clonal Diversity of the Current Prevalent Invasive Serogroup 6 Pneumococcal Serotype, 6C, in the United States in 1999 and 2006 to 2007 , 2009, Journal of Clinical Microbiology.

[6]  G. Hanquet,et al.  Temporal Trends of Invasive Streptococcus pneumoniae Serotypes and Antimicrobial Resistance Patterns in Spain from 1979 to 2007 , 2009, Journal of Clinical Microbiology.

[7]  H. de Lencastre,et al.  Temporal Trends and Molecular Epidemiology of Recently Described Serotype 6C of Streptococcus pneumoniae , 2008, Journal of Clinical Microbiology.

[8]  D. Grobbee,et al.  Rationale and design of CAPITA: a RCT of 13-valent conjugated pneumococcal vaccine efficacy among older adults. , 2008, The Netherlands journal of medicine.

[9]  Ziyong Sun,et al.  Serotype distribution and antimicrobial resistance patterns of Streptococcus pneumoniae isolated from children in China younger than 5 years. , 2008, Diagnostic microbiology and infectious disease.

[10]  Michael R. Jacobs,et al.  Prevalence of Serotype 19A Streptococcus pneumoniae among Isolates from U.S. Children in 2005-2006 and Activity of Faropenem , 2008, Antimicrobial Agents and Chemotherapy.

[11]  W. Schaffner,et al.  Population snapshot of emergent Streptococcus pneumoniae serotype 19A in the United States, 2005. , 2008, The Journal of infectious diseases.

[12]  A. Forsgren,et al.  Protein D of Haemophilus influenzae: a protective nontypeable H. influenzae antigen and a carrier for pneumococcal conjugate vaccines. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  M. Nahm,et al.  A rapid pneumococcal serotyping system based on monoclonal antibodies and PCR. , 2008, Journal of medical microbiology.

[14]  S. Kim,et al.  Streptococcus pneumoniae Serotype 19A in Children, South Korea , 2008, Emerging infectious diseases.

[15]  M. Nahm,et al.  Low prevalence of recently discovered pneumococcal serotype 6C isolates among healthy Dutch children in the pre-vaccination era. , 2008, Vaccine.

[16]  J. Scott,et al.  Pneumococcal Serotype Epidemiology , 2008 .

[17]  G. Siber,et al.  Pneumococcal vaccines: the impact of conjugate vaccine. , 2008 .

[18]  C. Ihekweazu,et al.  Trends in incidence of pneumococcal disease before introduction of conjugate vaccine: South West England, 1996–2005 , 2007, Epidemiology and Infection.

[19]  E. Lewis,et al.  Surveillance for Invasive Pneumococcal Disease During 2000–2005 in a Population of Children Who Received 7-Valent Pneumococcal Conjugate Vaccine , 2007, The Pediatric infectious disease journal.

[20]  In Ho Park,et al.  Genetic Basis for the New Pneumococcal Serotype, 6C , 2007, Infection and Immunity.

[21]  D. Isaacman,et al.  Indirect effects associated with widespread vaccination of infants with heptavalent pneumococcal conjugate vaccine (PCV7; Prevnar). , 2007, Vaccine.

[22]  In Ho Park,et al.  Discovery of a New Capsular Serotype (6C) within Serogroup 6 of Streptococcus pneumoniae , 2007, Journal of Clinical Microbiology.

[23]  J. Giesecke,et al.  THE SCIENTIFIC PANEL ON VACCINES AND IMMUNISATION , 2007 .

[24]  D. Musher Pneumococcal vaccine--direct and indirect ("herd") effects. , 2006, The New England journal of medicine.

[25]  Samir Shah,et al.  Emergence of vaccine-related pneumococcal serotypes as a cause of bacteremia. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[26]  P. Larsson,et al.  Serotypes of Streptococcus pneumoniae isolated from blood and cerebrospinal fluid related to vaccine serotypes and to clinical characteristics , 2006, Scandinavian journal of infectious diseases.

[27]  Tamara Pilishvili,et al.  Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. , 2005, JAMA.

[28]  A. Speciale,et al.  Antibiotic susceptibility and serotype distribution in Streptococcus pneumoniae circulating in Italy: results of the SEMPRE surveillance study (2000-2002). , 2005, International journal of antimicrobial agents.

[29]  A. Melegaro,et al.  Antibody responses to nasopharyngeal carriage of Streptococcus pneumoniae in adults: a longitudinal household study. , 2005, The Journal of infectious diseases.

[30]  D. Feikin,et al.  Epidemiological differences among pneumococcal serotypes. , 2005, The Lancet. Infectious diseases.

[31]  B. Spratt,et al.  Evolutionary Genetics of the Capsular Locus of Serogroup 6 Pneumococci , 2004, Journal of bacteriology.

[32]  B. Spratt,et al.  Temporal and geographic stability of the serogroup-specific invasive disease potential of Streptococcus pneumoniae in children. , 2004, The Journal of infectious diseases.

[33]  H. Humphreys,et al.  Antimicrobial susceptibility of invasive isolates of Streptococcus pneumoniae in Ireland. , 2004, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[34]  Steven Black,et al.  Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. , 2003, The Journal of pediatrics.

[35]  H. Humphreys,et al.  Penicillin Susceptibility and Epidemiological Typing of Invasive Pneumococcal Isolates in the Republic of Ireland , 2003, Journal of Clinical Microbiology.

[36]  B. Spratt,et al.  Clonal relationships between invasive and carriage Streptococcus pneumoniae and serotype- and clone-specific differences in invasive disease potential. , 2003, The Journal of infectious diseases.

[37]  J. Hedlund,et al.  Effects of a large-scale intervention with influenza and 23-valent pneumococcal vaccines in adults aged 65 years or older: a prospective study , 2001, The Lancet.

[38]  D. Crook,et al.  Invasive pneumococcal disease in England and Wales: vaccination implications. , 2001, The Journal of infectious diseases.

[39]  M. Ferraro Performance standards for antimicrobial susceptibility testing , 2001 .

[40]  G. Siber,et al.  Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[41]  D. Greenberg,et al.  Reduction of nasopharyngeal carriage of pneumococci during the second year of life by a heptavalent conjugate pneumococcal vaccine. , 1996, The Journal of infectious diseases.

[42]  A J Hall,et al.  Serogroup-specific epidemiology of Streptococcus pneumoniae: associations with age, sex, and geography in 7,000 episodes of invasive disease. , 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[43]  S. Gove,et al.  Potential interventions for the prevention of childhood pneumonia: geographic and temporal differences in serotype and serogroup distribution of sterile site pneumococcal isolates from children--implications for vaccine strategies. , 1995, The Pediatric infectious disease journal.

[44]  L. Smart,et al.  Pneumococcal serotyping. , 1989, The Journal of infection.